• MLN8237 (Alisertib): Assay Workflow Guide

  2026-09-29

  This scenario-driven guide explains how MLN8237 (Alisertib), SKU A4110, can support interpretable Aurora A inhibition, viability, proliferation, and apoptosis experiments. It covers formulation, dose design, orthogonal validation, cross-domain limitations, and practical vendor-selection criteria.

• Sodium Orthovanadate in Insulin Signaling Assays

  2026-09-29

  Sodium Orthovanadate is more than a phosphorylation-preserving reagent: it can separate true cellular signaling from post-lysis signal drift. This guide connects Na3VO4 chemistry with adipocyte insulin-signaling readouts, assay controls, and practical workflow decisions.

• NU6300 Targets GSDMD Cys191 to Block Pyroptosis

  2026-09-28

  The reference study identifies NU6300 as a covalent GSDMD inhibitor that reacts with cysteine-191 and interferes with cleavage, palmitoylation, membrane localization, and oligomerization. Its pathway-dependent effects in inflammasome models, together with activity in colitis and sepsis models, provide a mechanistic framework for developing pyroptosis-directed anti-inflammatory compounds.

• 5-Azacytidine Triggers DNA Damage in Myeloma

  2026-09-28

  A preclinical study found that 5-azacytidine induces ATR-associated DNA damage responses and apoptosis in multiple myeloma cells, including therapy-resistant models. Its reported activity and synergy with doxorubicin or bortezomib support further investigation, while the in vitro evidence does not establish clinical benefit.

• LG 101506: RXR Modulator Workflows in TNBC

  2026-09-27

  Use LG 101506 to test whether RXR modulation changes cellular phenotypes in cancer and metabolism models—not to assume a proven effect on PD-L1. This workflow pairs controlled compound handling with orthogonal RXR, checkpoint, and immune-cell readouts, while separating established TNBC findings from new hypotheses.

• Topotecan HCl: Practical Assay Design

  2026-09-26

  A scenario-driven guide to using Topotecan HCl (SKU B2296) in viability, proliferation, and cytotoxicity workflows. It covers mechanism, concentration and solvent planning, interpretation limits, and practical criteria for selecting a supplier without overstating what the available data establish.

• MLN2238: Mapping Proteasome Stress Signaling

  2026-09-25

  Explore how MLN2238, a potent proteasome β5 subunit inhibitor, can reveal the signaling response to proteotoxic stress. This article connects proteasome perturbation with ROS–JNK–CREB biology while distinguishing established findings from practical assay hypotheses.

• Spectrophotometric Assays for Alfuzosin–Tadalafil

  2026-09-25

  Alqahtani and colleagues developed the first reported spectrophotometric methods for quantifying alfuzosin hydrochloride and tadalafil together in a binary mixture. Their absorbance-subtraction and ratio-difference approaches address overlapping spectra and were validated for tablet analysis, offering simpler alternatives to more instrument-intensive assays without establishing clinical or pharmacological effects.

• BKT140 (BL-8040) in CXCR4 Oncology Workflows

  2026-09-24

  Build functional CXCR4 studies around BKT140 (BL-8040): connect receptor expression with chemotaxis, survival, and cell-mobilization readouts. Practical starting conditions and troubleshooting guidance help distinguish target engagement from assay artifacts while keeping imaging evidence in its proper translational context.

• DMXAA and the Endothelial Logic of Tumor Control

  2026-09-24

  DMXAA (Vadimezan) offers a way to interrogate tumor-vessel injury, angiogenic signaling, and cell-death responses. Here, we connect its reported pharmacology to new evidence on endothelial STING-JAK1 biology—while keeping the evidence boundaries clear for translational study design.

• MLN2238: From Proteasome Blockade to Stress Signaling

  2026-09-23

  Explore MLN2238 as a proteasome β5 subunit inhibitor and a tool for studying how proteotoxic stress reshapes cellular signaling. This article connects its target profile with CRTC–CREB findings and practical assay choices, while distinguishing established evidence from cross-model hypotheses.

• MLN2238: From β5 Selectivity to Stress Signals

  2026-09-23

  MLN2238 is a proteasome β5 subunit inhibitor that enables researchers to connect catalytic-site inhibition with ROS, JNK, CREB, and proteostasis outcomes. This article presents a layered assay strategy for distinguishing direct proteasome effects from adaptive stress signaling in oncology and protein-aggregation models.

• Disulfiram Workflows for Proteasome and Cancer Research

  2026-09-22

  Disulfiram enables paired studies of copper-sensitive proteasome inhibition, apoptotic cancer cell death, and inflammasome-linked pyroptosis. This workflow emphasizes matched controls, orthogonal readouts, and practical handling conditions for more interpretable cancer research.

• IBDV VP3 Disrupts IRF7 Antiviral Signaling

  2026-09-22

  The 2025 Frontiers in Cellular and Infection Microbiology study identifies IBDV VP3 as a viral factor that suppresses IRF7-dependent type I interferon signaling and promotes viral replication through proteasome-associated IRF7 degradation. Its paired infection, genetic perturbation, inhibitor, and protein-interaction experiments provide a useful framework for studying how viral proteins redirect host protein-stability pathways.

• SARS-CoV-2 ORF3a Q57H Dampens Apoptosis

  2026-09-21

  The reference study shows that the SARS-CoV-2 ORF3a-Q57H variant reduces pro-apoptotic activity through altered protein localization and weaker activation of the extrinsic apoptotic pathway, rather than through markedly lower total protein expression. Its design separates abundance from function and provides a useful framework for interpreting apoptosis assays and caspase activity measurement in virus–host cell studies.

8586 records 1/573 page Next 12345 下5页 Last page